Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-AAT in healthy volunteers
NCT03362242Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing ARO-AAT with Placebo (2 arms). Primary endpoint: Adverse Events Possibly or Probably Related to Treatment at 113 days. Started Mar 2018; status: completed.
02
Drugs
fazirsiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03362242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362242.